Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Asset disposition
Quarterly results
CC transcript
ACADIA PHARMACEUTICALS INC (ACAD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/02/2023 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ net product sales of $23.2 million - 2Q23 NUPLAZID® net product sales of $142.0 million - Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO, CA, August 2, 2023"
07/18/2023 8-K Quarterly results
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
06/12/2023 144 Form 144 - Report of proposed sale of securities:
05/24/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 26.5% stake in ACADIA Pharmaceuticals Inc.
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 - Announced DAYBUE Availability on April 17, 2023 SAN DIEGO, CA, May 8, 2023"
03/13/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 2.6% stake in ACADIA PHARMACEUTICALS INC
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.2% stake in ACADIA Pharmaceuticals Inc.
02/09/2023 SC 13G/A FMR LLC reports a 5.8% stake in ACADIA PHARMACEUTICALS INC
01/17/2023 SC 13D/A BAKER BROS. ADVISORS LP reports a 26.1% stake in ACADIA Pharmaceuticals Inc.
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
10/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/08/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/25/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/13/2022 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/04/2022 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results - 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO, CA, May 4, 2022"
05/04/2022 CT ORDER Form CT ORDER - Confidential treatment order:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/01/2022 10-K Annual Report for the period ended December 31, 2021
02/28/2022 8-K Quarterly results
02/14/2022 SC 13G PRICE T ROWE ASSOCIATES INC reports a 5.9% stake in ACADIA PHARMACEUTICALS INC
02/09/2022 SC 13G/A VANGUARD GROUP INC reports a 7.7% stake in ACADIA Pharmaceuticals Inc.
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy